Nothing Special   »   [go: up one dir, main page]

Yurko et al., 2009 - Google Patents

Design of biomedical nanodevices for dissolution of blood clots

Yurko et al., 2009

Document ID
10913768685801334047
Author
Yurko Y
Maximov V
Andreozzi E
Thompson G
Vertegel A
Publication year
Publication venue
Materials Science and Engineering: C

External Links

Snippet

Currently, tissue plasminogen activator (tPA) is administered intravenously after myocardial infarction and stroke to ensure blood-clot dissolution. One problem associated with such treatment is systemic toxicity of tPA, which can act upon plasminogen both in circulation and …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/30—Macromolecular compounds
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein

Similar Documents

Publication Publication Date Title
Morgan et al. Tissue-factor targeted peptide amphiphile nanofibers as an injectable therapy to control hemorrhage
US20100272740A1 (en) Micro- and nanoscale devices for delivery of active fibronolytic agents
Napoli et al. Glucose-oxidase based self-destructing polymeric vesicles
Kalafatovic et al. MMP-9 triggered self-assembly of doxorubicin nanofiber depots halts tumor growth
Zhang et al. Protease-modulated cellular uptake of quantum dots
Kulkarni et al. Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer
McCarthy et al. Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy
JP4988115B2 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
Vaidya et al. Platelets directed liposomes for the delivery of streptokinase: development and characterization
Gustafson et al. Synthesis and characterization of a matrix-metalloproteinase responsive silk–elastinlike protein polymer
Absar et al. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis
CA1335361C (en) Thrombus-targeted complexes of plasminogen activator and fibrin fragments
US20140364368A1 (en) Stimulus responsive nanocomplexes and methods of use thereof
Wang et al. Synthesis, characterization, and in vitro activity of dendrimer− Streptokinase conjugates
Oettl et al. Comparative characterization of bovine testicular hyaluronidase and a hyaluronate lyase from Streptococcus agalactiae in pharmaceutical preparations
Nguyen et al. Delivery of lipid micelles into infarcted myocardium using a lipid-linked matrix metalloproteinase targeting peptide
Li et al. RGD modified protein–polymer conjugates for pH-triggered targeted thrombolysis
Yurko et al. Design of biomedical nanodevices for dissolution of blood clots
Seo et al. A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots
Absar et al. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis
Chapurina et al. Streptokinase@ alumina nanoparticles as a promising thrombolytic colloid with prolonged action
Meyenburg et al. Fibrin encapsulated liposomes as protein delivery system: studies on the in vitro release behavior
Guan et al. Thrombus-targeting polymeric nanocarriers and their biomedical applications in thrombolytic therapy
Irshad et al. Recent trends and development in targeted delivery of therapeutics through enzyme responsive intelligent nanoplatform
Becker The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes